Loading...

ARDX ARDELYX INC US FDA Inspections 8-K Filing

RDLY

RDX

ARDELYX INC

(ARDX)

2023 8-K

Financial Results Update

Financial Update

Management Changes

Financial Results Released

Leadership Change

Debt-Equity Swaps

Financial Statements

Financial Results

Q4 Earnings Report

Management Change

Financial Results

New Lease Agreement

Supply Agreement

Earnings Reports

Approval of Amendment and R...

Earnings Reports

Funding Received

Financial Results Announcement

Financial Results

Resignation of Director

Financial Results Announcement

Loan Agreement Amendment

Other Special Situation

Financial Results Announcement

Amendment to Increase Autho...

FDA Accepts Resubmission of...

Financial Results Announcement

Financial Results Announcement

Loan Agreement Amendment

Agreement with Jefferies LLC

External Links:

ARDELYX, INC. announced that the FDA has accepted its resubmission of a New Drug Application for XPHOZAH for the control of serum phosphate in adult patients with chronic kidney disease on dialysis.

AI Assistant

ARDELYX INC

2023

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.